

Index

a

- abetalipoproteinemia 188–189
- ablative therapy 45
- acid fast stains (AFB) 236
- acrodermatitis enteropathica (AE) 164–165
- acute (erosive/hemorrhagic) gastritis 75–76
- adenocarcinoma 127, 211, 333, 361–362
 - anal duct 353–354
 - Barrett's esophagus 35, 37, 38, 39, 42–43
 - clinical features and endoscopic characteristics 39
 - colorectal 201, 300, 316, 354
 - definition 39
 - differential diagnosis 46, 47
 - evolution and clinical management 46
 - gastric 78, 80, 81, 99, 103, 104, 112, 125, 128–130, 132, 133
 - general features 39
 - hamartomatous polyposis patient 110, 111
 - herniated gastric mucosa 105
 - intestinal type 129, 130, 212–214
 - invasive 127, 268, 300, 318, 321
 - malignant colorectal polyp 320, 321
 - molecular techniques 46
 - mucinous 129, 130, 268, 333, 353, 354
 - pancreaticobiliary type 213, 214
 - papillary 129, 132
 - prognosis 46
 - prostate 319, 323
 - pyloric gland type 213–214
 - rectal 349, 350
 - serrated 316
 - tubular 129, 130
- adenocarcinoma of the stomach
 - clinical features and endoscopic characteristics 129
 - definition 128–129
 - differential diagnosis 132–133
 - evolution and clinical management 133
 - general features and predisposing factors 128–129
 - immunohistochemical studies and molecular features 132
 - microscopic features 129–132
 - prognosis 133
- adenoma 128, 209
 - Barrett's esophagus 42
 - Brunner gland 209, 210
 - clinical features and endoscopic characteristics 105–106
 - colonic 39, 106, 113, 211
 - conventional *see* conventional adenoma
 - definition 105
 - evolution and clinical management 107
 - gastric 105–108
 - general features 105
 - intestinal type 106, 211, 212
 - microscopic features 106–107
 - polyposis-associated gastric polyps 107–108
 - prognosis 107
 - pyloric gland 80, 106, 107, 195, 209–211, 213
 - rectal 331, 341
 - serrated 42, 211, 212, 302, 305, 321
 - tubulovillous adenomas of the colorectum 42
 - tubular adenoma of duodenum 211
- adenomatous polyps. *See* conventional adenomas
- adenovirus 170, 240
- alpha-methylacyl-CoA racemase (AMACR) immunoreactivity 46
- alveolar soft part sarcoma (ASPS) 58
- amebiasis 244
- amyloidosis 187–188
 - clinical features and endoscopic characteristics 89
 - microscopic features 89–90
- anal abscesses 340–341
- anal fissures 337
- anal intraepithelial neoplasia (AIN)/anal squamous intraepithelial lesion (ASIL) 354–356
- anal (rectal) tonsil 338–339
- angiectasia 204
- anorectal lymphomas 364
- anorectal tuberculosis 342
- antibiotic-associated colitis (AAC)/antibiotic-associated diarrhea (AAD) 240–243
- arteriosclerosis of vessels 90
- arteriovenous malformation 204
- aspergillosis 247
- atypical lipomatous tumor (ALT) 60
- autoimmune enteropathy 173–174
- autoimmune gastritis 75
 - clinical features and endoscopic characteristics 79
 - definition 79
 - differential diagnoses 81
 - evolution and clinical management 81
 - general features 79
 - immunohistochemical studies and molecular features 81
 - microscopic features 80
 - predisposing factors 79
 - prognosis 81

b

bacterial esophagitis 12, 14
 balantidium 244
 Barrett's esophagus (BE) 2, 4, 5
 adenocarcinoma 39
 adenoma 42
 clinical features and endoscopic characteristics 35–36
 crypt dysplasia 41
 definition 35
 differential diagnosis 38
 evolution and clinical management 38
 heterotopias 55
 with high-grade dysplasia 44, 45
 general features 35
 immunohistochemical studies 37–38
 intramucosal and invasive adenocarcinoma 42–43
 with low-grade dysplasia 45
 microscopic features 36–37
 molecular features 37–38
 with flat neoplasia 6
 non-dysplastic 6, 39, 45
 prognosis 38
 risk factors 35
 scleroderma-associated chronic GERD 28
 basal crypt dysplasia-like atypia. *See* crypt dysplasia
 basal gland dysplasia. *See* crypt dysplasia
 B-cell non-hodgkin lymphoma
 B-chronic lymphocytic leukemia/small lymphocytic lymphoma 226–227
 Burkitt lymphoma 224–226
 diffuse large B-cell lymphoma 223–224
 extranodal marginal zone mucosa-associated lymphoid tissue lymphoma 223
 follicular B-cell lymphoma 221–223
 mantle cell lymphoma 223
 BE. *See* Barrett's esophagus (BE)
 Behcet's disease 27, 185
 biopsy forceps trauma 76
 blastomycosis 247
 bowenoid papulosis 356
 Bowen's disease 356
 brainerd diarrhea 242
 British Society of Gastroenterology (BSG) 35
 "Brown bowel" syndrome 186
 Brunner gland adenoma 209, 210
 Brunner's gland cyst 199, 200

bullous diseases 27, 28
 Burkitt lymphoma
 clinical features and endoscopic characteristics 154
 definition 154
 differential diagnosis 154
 evolution and clinical management 154–155
 general features and predisposing factors 154
 immunohistochemical and molecular features 154
 microscopic features 154
 prognosis 154–155

c

Candida 13–14
 CCS. *See* Cronkhite–Canada syndrome (CCS)
 CD117 137
 celiac disease
 clinical features/endoscopic characteristics 171–172
 definition 171
 differential diagnosis 173
 general features (frequency) and predisposing factors 171
 microscopic features 172–173
 treatment 173
 chancroid 345
 chemical (reactive) gastritis/gastropathy 76–77
 chemical gastropathy 76
 chemoradiation 87
 chemoradiotherapy-related atypia 126
 chlamydia/lymphogranuloma venereum 250
Chlamydia trachomatis proctitis 250
 chronic variable immunodeficiency (CVID) 176
 CMV. *See* cytomegalovirus (CMV)
 colchicine 86
 collagenous colitis 84, 255, 258–260, 263, 265, 266, 268
 differential diagnosis of 261
 variant patterns of 260
 collagenous gastritis
 clinical features and endoscopic characteristics 84
 definition 84
 differential diagnosis 84–85
 evolution and clinical management 85
 histo- and immunohistochemical studies 84
 microscopic features 84
 prognosis 85
 collagenous sprue 178
 colon 8, 9
 colorectal carcinomas
 clinical features and endoscopic characteristics 322
 definition 321–322
 differential diagnosis 326–328
 general features and predisposing factors 321–322
 immunohistochemical studies 324–326
 microscopic features 322–324
 condyloma acuminatum 352–353
 conventional adenoma
 clinical features and endoscopic characteristics 307–308
 definitions 307
 differential diagnosis 310
 evolution and clinical management 310
 general features 307
 immunohistochemical studies and molecular features 310
 microscopic features 308–310
 prognosis 310
 Cowden's disease 110–111
 Crohn's colitis 296
 Crohn's disease (CD) 75, 78, 179–180
 clinical presentation 290
 microscopic findings 292–293
 morphologic variants 293
 Cronkhite–Canada syndrome (CCS) 90, 111–112, 201–202, 317
 cryptal lymphocytic colitis 263
 crypt dysplasia 41
Cryptococcus neoformans 247, 249
 cryptogenic multifocal ulcerating and stenosing enteritis (CMUSE) 185–186
 cryptosporidia 244
 cryptosporidiosis 165–166
 CVID. *See* chronic variable immunodeficiency (CVID)
 cyclin D1 153
 cytomegalovirus (CMV) 12, 14, 82, 170–171, 237–239

d

deposition disorders 186–187
 dermatological diseases

- definition 26–27
- general features 26–27
- microscopic and immunofluorescence features 27–28
- Dieulafoy's lesion 204
- diffuse large B-cell lymphoma (DLBCL) 146
 - clinical features and endoscopic characteristics 148
 - definition 148
 - differential diagnosis 150
 - evolution and clinical management 150
 - general features and predisposing factors 148
 - immunohistochemical and molecular features 148–150
 - microscopic features 148
 - prognosis 150
- diversion proctocolitis 255–257
- diverticulosis
 - clinical features 265–266
 - complications 266
 - definition 265
 - differential diagnosis 266–267
 - microscopic features 266
 - risk factors 265, 266
 - treatment/prognosis/evolution 267
- DLBCL. *See* diffuse large B-cell lymphoma (DLBCL)
- donovanosis. *See* granuloma inguinale
- doxycycline 86
- drug-associated and iatrogenic colitis 270–271
- drug-induced esophagitis
 - clinical and endoscopic characteristics 21, 22
 - definition 21
 - differential diagnosis 22–23
 - evolution and clinical management 23
 - general features 21, 22
 - microscopic features 22
 - prognosis 23
- dysphagia 27
- dysplasia 48, 304–306, 341
 - adenomatous hyperplasia 80
 - Barrett's esophagus 37–46
 - clinical features and endoscopic characteristics 39, 125, 126
 - colon 8
 - conventional adenomas 299, 300
 - definition 39, 125
 - differential diagnosis 46, 47, 125–126
 - evolution and clinical management 46, 126–128
 - fundic gland polyps 99, 101
 - gastric adenomas 106
 - gastric foveolar type adenoma 107
 - in gastric mucosa 125–127
 - general features 39, 125
 - immunohistochemical studies 45–46
 - inflammatory bowel disease 299–303
 - intestinal epithelial dysplasia 164
 - intestinal type adenoma 106
 - microscopic features 125–127
 - molecular techniques 46
 - morphologic diagnosis 39
 - high-grade dysplasia 41
 - indefinite 39–40
 - low-grade intestinal-type 40
 - negative biopsies 39
 - perianal 346
 - perianal intraepithelial neoplasia 348
 - predisposing factors 125
 - prognosis 46, 126–127
 - pyloric gland adenomas 107
 - squamous cell 46–53
 - tubulovillous adenoma 300, 301
 - variants 41–42
- e**
- early gastric cancer
 - clinical features and endoscopic characteristics 127
 - definition 127
 - evolution and clinical management 128
 - general feature 127
 - microscopic features 127
 - predisposing factors 127
 - prognosis 128
- elastofibromatous polyp 317, 318
- emphysematous 82
- endometriosis 198, 310, 317
- endoscopic mucosal resection (EMR) 43–44
- endoscopic submucosal dissection (ESD) 43–44
- endoscopy 289
- Entamoeba histolytica* infection 244
- enteropathy 157
- enteropathy-associated T-cell lymphoma (EATL) 155
- enteropathy-type T-cell lymphoma (ETTL) 227–228
- environmental metaplastic atrophic gastritis (EMAG) 7
- eosinophilic colitis 271
- eosinophilic conditions affecting the colon
 - clinical and endoscopic features 271–276
 - definition 271
 - differential diagnosis 276–277
 - general features and predisposing factors 271
 - microscopic features 276
 - prognosis and evolution 277
 - treatment 277
- eosinophilic enteritis 181
- eosinophilic esophagitis (EOE)
 - clinical features and endoscopic characteristics 18
 - clinical management 20
 - definition 17–18
 - differential diagnosis 19–20
 - evolution 20
 - features 17–18
 - immunohistochemical studies 19
 - microscopic features 18–19
 - prognosis 20
- eosinophilic gastritis
 - clinical features and endoscopic characteristics 83
 - definition 83
 - differential diagnosis 83–84
 - evolution and clinical management 84
 - microscopic features 83
 - prognosis 84
- eosinophilic gastroenteritis 271
- epidermolysis bullosa 27, 28
- epithelial polyps
 - conventional adenoma
 - clinical features and endoscopic characteristics 307–308
 - definitions 307
 - differential diagnosis 310
 - evolution and clinical management 310
 - general features 307
 - immunohistochemical studies and molecular features 310
 - microscopic features 308–310
 - prognosis 310
 - inflammatory and hyperplastic polyps 53–54
 - serrated polyps

epithelial polyps (*cont'd*)

- clinical features and endoscopic characteristics 310
- definitions 310
- differential diagnosis 313
- evolution and clinical management 313
- general features 310
- immunohistochemical studies and molecular features 312–313
- microscopic features 310–312
- prognosis 313
- squamous papilloma 54–55
- Epstein–Barr virus (EBV) 80
- esophageal lymphoma
 - clinical features and endoscopic characteristics 63–64
 - definition 63
 - differential diagnosis 65
 - general features 63
 - immunohistochemical studies 64
 - microscopic features 64
 - molecular features 64
 - predisposing factors 63
 - prognosis, evolution and clinical management 65
- esophagitis 28–29
- esophagus. *See also* Barrett's esophagus (BE)
 - diagnostic sampling 5–6
 - therapeutic sampling 6–7
- extramammary Paget's disease 356–358
- extranodal NK/T-cell lymphoma (ENKTCL) 155, 228

f

- familial adenomatous polyposis 199
- fecal microbial transplantation (FMT) 242
- FGPs. *See* fundic gland polyps (FGPs)
- fibroblastic polyp 316
- fibroepithelial polyp 350–351
- fine-needle aspiration (FNA) devices 4
- fluorescence in situ hybridization (FISH) 46
- focal active colitis (FAC) 253–254
- food protein-induced enteropathy 180–181
- foveolar dysplasia 41–42. *See also* non-adenomatous dysplasia
- fulminant colitis 293
- fundic gland polyps (FGPs) 99–100
- fungal esophagitis 11
- fungi 246

g

- gangliocytic paraganglioma
 - clinical features/endoscopic characteristics 216
 - definition 216
 - differential diagnosis 217
 - general features 216
 - immunohistochemical and molecular features 217
 - microscopic features 216
 - spread 218
 - treatment/prognosis/evolution 218
- ganglioneuromatous polyposis 202–203
- GAPPS. *See* gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
- gastral antral vascular ectasia (GAVE) 88
- gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) 112–113
- gastric foveolar type adenoma 106, 107
- gastric mucosal prolapse polyps 104
- gastric polyps 7
- gastritides with prominent lympho(plasma)cytic infiltrate. *See* autoimmune gastritis
- gastritis cystica polyposa/profunda 104, 105
- gastroesophageal reflux disease (GERD)
 - clinical features and endoscopic characteristics 15–16
 - clinical management 17
 - definition 15
 - differential diagnosis 17
 - microscopic features 16
 - prognosis and evolution 17
 - risk factors 15
- gastrointestinal stromal tumor (GIST) 61
 - clinical features and endoscopic characteristics 136
 - clinical features/endoscopic characteristics 218
 - definition 136, 218
 - differential diagnosis 137–138, 220
 - evolution and clinical management 138
 - general features and predisposing factors 136
 - general features (frequency) and predisposing factors 218
 - immunohistochemical and molecular features 219–220
 - immunohistochemical studies and molecular features 137
 - microscopic features 136–137, 219
 - prognosis 138
 - spread 220
 - treatment/prognosis/evolution 220
- GCT. *See* granular cell tumor (GCT)
- germinal center B-cell like (GCB) 150
- GFPs. *See* giant fibrovascular polyps (GFPs)
- giant condyloma of Buschke and Löwenstein. *See* verrucous carcinoma
- giant fibrovascular polyps (GFPs) 60–61
- giardiasis 165
- GIST. *See* gastrointestinal stromal tumor (GIST)
- glycogenic acanthosis 56–57
- gonorrhea 249
- graft *versus* host disease (GVHD) 86, 87, 177
 - clinical and endoscopic characteristics 25
 - clinical and endoscopic features 278
 - definition 24–25, 278
 - differential diagnosis 25–26, 282
 - evolution and clinical management 26
 - general features 24–25
 - general features and predisposing factors 278
 - microscopic features 25, 278, 280–281
 - prognosis 26
 - signs and symptoms 279–280
 - treatment and prognosis 282
- granular cell tumor (GCT)
 - clinical features and endoscopic characteristics-GI 57
 - definition 57
 - differential diagnosis 58
 - evolution and clinical management 58
 - general features 57
 - immunohistochemical studies 58
 - microscopic features 58
 - molecular features 58
 - predisposing factors 57
 - prognosis 58
- granulocytic sarcoma 230
- granuloma inguinale 344–345
- granulomatous gastritis
 - clinical features and endoscopic characteristics 77–78

- definition 77
 - differential diagnosis 78–79
 - evolution and clinical management 79
 - general features 77
 - microscopic features 78
 - predisposing factors 77
 - prognosis 79
- h**
- hamartoma 197–198
 - hamartomatous polyps 314
 - Helicobacter heilmannii* gastritis 75
 - Helicobacter pylori* (HP) gastritis
 - clinical features 73
 - definition 73
 - differential diagnosis 75
 - endoscopic characteristics 73
 - evolution and clinical management 75
 - general features 73
 - immunohistochemical studies 74
 - microscopic features 73–74
 - molecular features 74
 - predisposing factors 73
 - prognosis 75
 - helminthic infections
 - aspergillosis 247
 - blastomycosis 247
 - fungi 246
 - histoplasmosis 246–249
 - mucormycosis 247 249
 - oxyuriasis 246
 - paracoccidioides 247
 - trematodes 245–246
 - hemangiomas 61–62
 - hematopoietic disorders with
 - plasmacytic differentiation 229
 - hemodialysis associated telangiectasia 204
 - hemorrhoids 337–338
 - herpes simplex virus (HSV) 11–12, 14, 82, 240, 345–346
 - heterotopias 55–57, 195
 - heterotopic pancreas 116–117
 - hidradenitis suppurativa 339–340
 - hidradenoma papilliferum 351
 - histiocytic disorders 231
 - histiocytic/granulomatous enteritis 181–182
 - histoplasmosis 246–249
 - Hodgkin lymphoma 228
 - human immunodeficiency virus (HIV) 171
 - hyperplastic hypersecretory
 - gastropathy 90
 - hyperplastic polyposis 105
 - hyperplastic polyps 53–54
 - clinical features and endoscopic characteristics 101
 - definition and general features 101
 - evolution and clinical management 103
 - microscopic features 102–103
 - prognosis 103
 - variants 103–105
 - hypertrophic gastropathy 88
- i**
- iatrogenic gastritis
 - clinical features and endoscopic characteristics 85
 - definition 85
 - evolution and clinical management 87–88
 - microscopic features 85–87
 - prognosis 87–88
 - iatrogenic injury 76
 - IBD. *See* inflammatory bowel diseases (IBD)
 - immunoglobulin A (IgA)
 - deficiency 176–177
 - indolent T-cell lymphoproliferative disorders 156–157
 - infectious gastritis 81–82
 - inflammatory bowel disease-associated polyps 314
 - inflammatory bowel diseases (IBD) 28–29, 341
 - clinical management 296
 - clinical presentation 288, 289
 - definition 288
 - differential diagnosis 294–296
 - dysplasia in 299–303
 - evolution 296
 - extraintestinal manifestations 288–289
 - general features and predisposing factors 288
 - prognosis 296
 - inflammatory cloacogenic polyp 349–350
 - inflammatory fibroid polyp 137
 - clinical features/endoscopic characteristics 220
 - definition 220
 - differential diagnosis 221
 - immunohistochemistry and
 - molecular features 221
 - microscopic features 221
 - inflammatory fibroid polyps 113–114
 - inflammatory fibroid tumors 317
 - inflammatory polyps 53–54, 313
 - intestinal epithelial dysplasia (IED) 164
 - intestinal ischemia 182
 - intestinal spirochetosis 237
 - intestinal type adenoma 211
 - intestinal type epithelium 106
 - intraepithelial neoplasia 48
 - inverted hyperplastic polyps 104–105
 - iron pill gastritis 85
 - ischemic and radiation gastritis 90
 - ischemic colitis 250–252
 - isolated ileitis/erosion 184–185
 - isospora 166
- j**
- juvenile polyposis (JP)
 - clinical features and endoscopic characteristics 109
 - definition 108–109
 - evolution and clinical management 109
 - microscopic features 109
 - molecular features 109
 - prognosis 109
 - juvenile polyposis syndrome 200–201
 - juvenile polyps 314, 316
- k**
- Kaposi sarcoma (KS) 62
 - kayexalate 22, 87
- l**
- Langerhans cell histiocytosis 231
 - Lanthanum carbonate 86
 - leiomyoma of the muscularis
 - mucosae 315, 316
 - leiomyomas/leiomyosarcoma 137
 - clinical features and endoscopic characteristics 59
 - definition 58–59
 - differential diagnosis 59–60
 - evolution and clinical management 60
 - general features 58–59
 - immunohistochemical studies 59
 - microscopic features 59, 60
 - molecular features 59
 - predisposing factors 58–59
 - prognosis 60

leukemia 230
 leukoplakia 352
 Lichen planus 27
 lipoma 114–115, 315–316
 Los Angeles Classification 15–16
 lymphocytic colitis 260–263
 lymphocytic duodenosis (LD) 161–162
 lymphocytic esophagitis 20–21
 lymphocytic gastritis 79
 lymphogranuloma venereum 343–344
 lymphoid hyperplasia 203
 lymphoid polyps 317
 lymphoma 221, 222
 lymphoma of the large bowel 332–334
 lymphoplasmacytic lymphoma 229
 lymphovascular invasion (LVI) 44

m

MAIC. *See Mycobacterium avium*
 intracellulare complex (MAIC)
 malakoplakia 231
 malignant colorectal polyps (MCPs)
 clinical features and endoscopic
 characteristics 328, 329
 definition 328
 differential diagnosis 329–330
 evolution and simple clinical
 management 330
 general features and predisposing
 factors 328
 immunohistochemical studies and
 molecular features 329
 microscopic features 328
 prognosis 330
 malignant melanoma 362–364
 mantle cell lymphoma 145, 150–154
 marginal zone B-cell lymphoma
 (MALT) lymphoma 75
 mastocytic enterocolitis 277–278
 mastocytosis 229–230
 melanoma 62
 Ménétrier's disease 117–118
 clinical features and endoscopic
 characteristics 88–89
 evolution and clinical management
 90–91
 microscopic features 89
 prognosis 90–91
 mesenchymal polyps 57–58, 314–317
 microscopic colitis (MC) 258
 microsporidiosis 166–167
 microvillus inclusion disease (MID) 163

mixed adenoneuroendocrine carcinoma
 (MANEC) 135
 mucormycosis 247, 249
 mucosa-associated lymphoid tissue
 (MALT) lymphoma
 b-cell non-hodgkin lymphoma 223
 clinical features and endoscopic
 characteristics 142
 definition 142
 differential diagnosis 144–146
 evolution and clinical
 management 146–148
 general features and predisposing
 factors 142
 immunohistochemical and molecular
 features 144
 microscopic features 142–144
 post-treatment evaluation 147–148
 prognosis 146–148
 mucosal calcinosis 86
 mucosal prolapse polyps 313–314
 mucosal prolapse/solitary rectal ulcer
 syndrome (MPSRUS) 267–268
 mucosal prolapse type polyps 199
 mycobacterial esophagitis 12, 14
Mycobacterium avium complex (MAC)
 236–237
mycobacterium avium intracellulare
 (MID) 167
Mycobacterium avium intracellulare
 complex (MAIC) 167–168
Mycobacterium tuberculosis 236
 mycophenolate 22

n

necrotizing enterocolitis (NEC) 182
 NETs. *See* neuroendocrine tumors (NETs)
 neural tumors 316–317
 neuroendocrine carcinoma
 (NEC) 135–136
 neuroendocrine neoplasms 330–332
 neuroendocrine tumors (NETs)
 clinical features and endoscopic
 characteristics 133
 clinical features/endoscopic
 characteristics 215
 definition 133, 214
 differential diagnosis 134, 215
 evolution and clinical
 management 134–135
 general features and predisposing
 factors 133, 214

immunohistochemical features 215
 immunohistochemical studies and
 molecular features 134
 microscopic features 133–134, 215
 prognosis 134–135
 treatment/prognosis/evolution 216
 neutropenic enterocolitis
 (typhlitis) 257–258
 NK-cell enteropathy 80–81
 NK-cell gastropathy 79, 157
 non-adenomatous dysplasia 41–42
 nonepithelial and malformative
 polypoid lesions 113–114
 nonepithelial tumors 136–138
 non-*Helicobacter pylori* (HP)
 infection 75
 non-idiopathic inflammatory colitides
 bacterial 236–237
 infectious colitis 235–236
 viral 237–240
 nonneoplastic vascular lesions 204–205
 NSAID enteropathy 184

o

obstructive colitis 269–270
 odynophagia 27
 oxyuriasis 246

p

PAIN. *See* perianal intraepithelial
 neoplasia (PAIN)
 pancreatic heterotopia 195–197
 papillary adenocarcinoma 129
 paracoccidioides 247
 parasites 244–245
 parasitic esophagitis 12
 PAS/D–PAS stains 133
 paucicellular lymphocytic colitis 263
 pemphigus vulgaris 27, 28
 peptic duodenitis 183–184
 peptic ulcer disease
 clinical features 73
 definition 73
 differential diagnosis 75
 endoscopic characteristics 73
 evolution and clinical management 75
 general features 73
 immunohistochemical studies 74
 microscopic features 73–74
 molecular features 74
 predisposing factors 73
 prognosis 75

- perianal intraepithelial neoplasia (PAIN) 356
- perineuriomas. *See* fibroblastic polyp
- peripheral T-cell lymphomas (PTCLs)
- abnormal immune states 157
 - clinical features and endoscopic characteristics 155
 - definition 155
 - evolution and clinical management 155
 - general features and predisposing factors 155
 - immunohistochemical and molecular features 155
 - indolent T/NK-cell lymphoproliferations 155–157
 - microscopic features 155
 - prognosis 155
- Peutz–Jeghers polyps 314, 316
- Peutz–Jeghers syndrome 200
- clinical features and endoscopic characteristics 110
 - definition 109–110
 - evolution and clinical management 110
 - microscopic features 110
 - prognosis 110
- phlegmonous colitis 82, 269
- pigment disorders 186
- plasmablastic lymphoma 229
- plasma cell neoplasia 146
- pneumatosis coli 268–269
- pneumatosis intestinalis 203–204
- polypoid dysplasia 42
- polypoid foveolar hyperplasia 103–104
- polyposis syndromes
- familial adenomatous polyposis 199
 - juvenile polyposis syndrome 200–201
 - Peutz–Jeghers syndrome 200
- polyps of the large intestine 307
- portal hypertensive enteropathy 204
- portal hypertensive gastropathy (PHG) 88
- primary lymphangiectasia 205
- primary sclerosing cholangitis (PSC) 288
- protozoan infections 244–245
- pseudomembranous colitis (PMC) 240–243
- pseudopolyp 198–199
- PTCL-NOS 155
- PTCLs. *See* peripheral T-cell lymphomas (PTCLs)
- PTEN hamartoma tumor syndrome 201, 314
- pyloric gland adenoma
- clinical features/endoscopic characteristics 209, 210
 - definition 209
 - differential diagnosis 210
 - microscopic features 209
 - predisposing factors 209
 - treatment/prognosis/evolution 210–211
- pyloric gland type adenoma 107
- pyogenic granuloma 204
- R**
- radiation enteritis 182–183
- radiation esophagitis 26
- radiation proctocolitis 254–255
- reactive lymphoid hyperplasia 144–145
- refractory celiac disease (RCD) 178–179
- S**
- sarcoidosis 78, 79
- schwannoma 137
- serrated dysplasia 42
- serrated polyps 211–212
- clinical features and endoscopic characteristics 310
 - definitions 310
 - differential diagnosis 313
 - evolution and clinical management 313
 - general features 310
 - immunohistochemical studies and molecular features 312–313
 - microscopic features 310–312
 - prognosis 313
- sexually transmitted infections
- chlamydia/lymphogranuloma venereum 250
 - Chlamydia trachomatis* proctitis 250
 - gonorrhea 249
 - syphilis 249–250
- sloughing esophagitis 23–24
- small B-cell lymphomas 145–146
- small intestinal bacterial overgrowth 175–176
- small intestine 7–8
- small intestine mucosa 231–232
- small lymphocytic lymphoma 145
- sodium polystyrene sulfonate 87
- squamous cell carcinoma 358–361
- clinical features and endoscopic characteristics 48
 - definition 46
 - differential diagnosis 52–53
 - evolution and clinical management 53
 - immunohistochemical studies 51–52
 - incidence 48
 - microscopic features 48–51
 - molecular features 51–52
 - prognosis 53
 - risk factors 47
- squamous hyperplasia 352
- squamous papilloma 54–55
- stomach 7
- adenocarcinoma of (*see* adenocarcinoma of the stomach)
 - gastric adenocarcinoma and proximal polyposis of the stomach 112–113
- strongyloidiasis 167
- superficial carcinomas 48–50
- syphilis 249–250, 342–343
- systemic sclerosis 90
- T**
- taxol-induced gastritis 86
- T-cell/NK-T cell non-Hodgkin lymphoma
- enteropathy-associated T-cell lymphoma 227–228
- extranodal NK/T-cell lymphoma 228
- ulcerative jejunoileitis 227
- tissue acquisition
- brush cytology 3–4
 - culture samples 5
 - cytology samples 5
 - endoscopic equipment 1–2
 - endoscopic snare devices 3
 - fine-needle aspiration devices 4
 - non-oriented samples 5
 - oriented samples 5
 - pinch biopsy forceps 2 3
- tissue processing, in endoscopy
- laboratory 4–5
- trematodes 245–246
- treponema pallidum (syphilitic) 80
- tropical sprue 174–175
- tuberculosis (TB) 78
- tubular adenocarcinoma 129
- type A gastritis. *See* autoimmune gastritis

u

- ulcerative colitis (UC)
 - clinical presentation 289–290
 - microscopic findings 290–292
 - morphologic variants 293
- ulcerative jejunoileitis 227
- ulcerative proctitis 296
- ulcer disease 7

v

- vascular abnormalities 204–205
- vascular gastropathy 88
- verrucous carcinoma 361

- viral esophagitis 11–12
- visceral leishmaniasis 244–245

w

- waldenstrom macroglobulinemia 186–187
- well-differentiated adenocarcinoma 210
- Whipple's disease 168, 169
- WHO classification
 - of small intestinal carcinoma 212
 - of small intestinal neuroendocrine tumors 215

x

- xanthoma 115–116, 231

y

- yersiniosis 168–169

z

- Zollinger–Ellison syndrome (ZES)
 - clinical features and endoscopic characteristics 89
 - evolution and clinical management 90–91
 - microscopic features 89
 - prognosis 90–91